Download PDF
Fortschr Neurol Psychiatr 2009; 77(4): 192-202
DOI: 10.1055/s-0028-1109214
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Antikonvulsiva in der Behandlung der Alkoholabhängigkeit

Anticonvulsants in the Treatment of AlcoholismU. Bonnet1, 2 , M. Schäfer3, 4 , C. Richter3 , J. Milkereit1 , J. Wiltfang2 , N. Scherbaum1 , B. Lieb1, 2
  • 1Arbeitsgruppe für klinische Suchtforschung an der Klinik für Psychiatrie und Psychotherapie, LVR-Klinikum Essen, Universität Duisburg-Essen
  • 2Klinik für Psychiatrie und Psychotherapie, LVR-Klinikum Essen, Universität Duisburg-Essen
  • 3Klinik für Psychiatrie und Psychotherapie, Charité – Universitätsmedizin Berlin, Charité Campus Mitte, Berlin
  • 4Klinik für Psychiatrie, Psychotherapie und Suchtmedizin, Kliniken Essen-Mitte, Ev. Huyssenstift, Essen
Further Information

Publication History

Publication Date:
03 April 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zur Behandlung der Alkoholkrankheit sind in den letzten 40 Jahren aufgrund richtungweisender Tierexperimente zunehmend klinische Studien mit Antikonvulsiva durchgeführt worden. An dieser Stelle werden die anhand einer ausführlichen Suche in MEDLINE, EMBASE und Cochrane gefundenen klinischen Studien mit dem Ziel vorgestellt, sie in Anlehnung an die Leitlinien der Arzneimittelkommission der deutschen Ärzteschaft zu bewerten. Betrachtet wurden klinische Studien zur Behandlung des Alkoholentzugssyndroms, zur Rückfallprävention bzw. Trinkmengenreduktion und zur Behandlung komorbider psychischer Störungen. Die Studienanalyse ergibt bisher keine sicheren Alternativen zu Benzodiazepinen, Clomethiazol und Carbamazepin in der alleinigen Behandlung des stärkeren Alkoholentzugssyndroms. Auch bezüglich der Rückfallprävention/Trinkmengenreduktion und Behandlung komorbider Störungen ist die Studienlage für Antikonvulsiva noch nicht zufriedenstellend. Die sichersten Wirksamkeitsnachweise liegen hier zurzeit für Topiramat (Trinkmengenreduktion) und Valproat (Alkoholkrankheit mit bipolarer Störung) vor, die allerdings noch durch hinreichend große kontrollierte Studien von längerer Dauer bestätigt werden müssen. Am Horizont scheinen Baclofen und einige Antikonvulsiva wie Valproat, Oxcarbazepin und Gabapentin ein vielversprechendes Potenzial zur unterstützenden Behandlung der Alkoholerkrankung zu bieten. Zu Levetiracetam, das aufgrund seines Sicherheitsprofils und seiner geringen Interaktionsbereitschaft besonders geeignet wäre, sind noch keine kontrollierten Studien publiziert.

Abstract

Because of promising data from animal studies the clinical trials on anticonvulsants for the treatment of alcohol disorder have been accumulating in the last 40 years. A comprehensive research of various data bases (MEDLINE, EMBASE, Cochrane) was performed. Here, we present the trials found together with an estimation of their evidence according to the guidelines of the “Arzneimittelkommission der deutschen Ärzteschaft”. We examined the clinical studies conducted for the treatment of alcohol withdrawal syndrome, for relapse prevention/consumption reduction as well as for the treatment of co-morbide psychiatric disorders. The study analysis has not resulted in any safe alternative to benzodiazepines, clomethiazole or carbamazepine in the treatment of the stronger alcohol withdrawal syndrome. The material is also insufficient with regard to relapse prevention/consumption reduction or to the treatment of co-morbide psychiatric disorders. The safest proof of effect is currently topiramate (consumption reduction) and valproate (alcohol dependence with bipolar disorder). However, first positive results must be confirmed in well controlled studies with a much longer duration. Baclofen und several anticonvulsants such as valproate, oxcarbazepine and gabapentin demonstrate a potential to aid in the treatment of alcohol disorder. Currently, there exists any published controlled study for levetiracetam, which would be well suited in the treatment of alcoholism due to its favorable safety profile and low pharmacological interaction potential.

Schlüsselwörter

Alkoholabhängigkeit - Alkohol - Antikonvulsiva - akutes und protrahiertes Entzugssyndrom - Rückfallprävention

Key words

alcoholism - alcohol - anticonvulsants - acute and protracted withdrawal symptoms - relapse prevention

Literatur

  • 1 Meyer C, John U. Alkohol – Zahlen und Fakten zum Konsum. Deutsche Hauptstelle für Suchtfragen e. V.- DHS, Jahrbuch Sucht 2007 Geesthacht; Neuland 2007: 23-50
    Google Scholar
  • 2 Kiefer F, Mann K. Diagnostik und Therapie der Alkoholabhängigkeit.  Fortschr Neurol Psychiatr. 2007;  75 33-46
    Google Scholar
  • 3 Wittchen H U, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies.  Eur Neuropsychopharmacol. 2005;  15 (4) 357-376
    Google Scholar
  • 4 Mundle G, Banger M, Mugele B. et al .Alkoholbezogene Störungen: Akutbehandlung. Schmidt LG, Gastpar M, Falkai P, Gaebel W Evidenzbasierte Suchtmedizin Köln; Deutscher Ärzte-Verlag 2006: 25-52
    Google Scholar
  • 5 Lopez A D, Mathers C D, Ezzati M. et al . Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.  Lancet. 2006;  367 1747-1757
    Google Scholar
  • 6 Davies D. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system.  J Psychiatry Neurosci. 2003;  28 263-274
    Google Scholar
  • 7 Becker H C. Alcohol withdrawal: neuroadaptation and sensitization.  CNS Spectrums. 1999;  4 38-65
    Google Scholar
  • 8 Krystal J H, Staley J, Mason G. et al . Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment.  Arch Gen Psychiatry. 2006;  63 957-968
    Google Scholar
  • 9 Tsai G, Coyle J T. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism.  Annu Rev Med. 1998;  49 173-184
    Google Scholar
  • 10 De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol.  Addictive Behav. 2004;  29 1325-1339
    Google Scholar
  • 11 Heinz A, Löber S, Georgi A. et al . Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake.  Alcohol. 2003;  38 35-39
    Google Scholar
  • 12 Duka T, Gentry J, Malcolm R. et al . Consequences of multiple withdrawals from alcohol.  Alcohol Clin Exp Res. 2004;  28 233-246
    Google Scholar
  • 13 Little H J, Stephens D N, Ripley T L. et al . Alcohol withdrawal and conditioning.  Alcohol Clin Exp Res. 2005;  29 453-464
    Google Scholar
  • 14 Malcolm R, Herron J E, Anton R A. et al . Recurrent detoxifications may elevate alcohol craving as measured by the obsessive compulsive drinking scale.  Alcohol. 2000;  20 181-185
    Google Scholar
  • 15 Satel S L, Kosten T R, Schuckit M A. et al . Should protracted withdrawal from drugs be included in DSM-IV?.  Am J Psychiatry. 1993;  150 695-704
    Google Scholar
  • 16 Aston-Jones G, Harris G C. Brain substrates for increased drug seeking during protracted withdrawal.  Neuropharmacology. 2004;  47 (Suppl 1) 167-179
    Google Scholar
  • 17 Carpenter-Hyland E P, Chandler J. Adaptive plasticity of NMDA receptors and dendritic spines: implications for enhanced vulnerability of the adolescent brain to alcohol addiction.  Pharmacol Biochem Behav. 2007;  86 200-208
    Google Scholar
  • 18 McBride W J, Li T K. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents.  Crit Rev Neurobiol. 1998;  12 339-369
    Google Scholar
  • 19 Ulrichsen J, Haugbol S, Brandt C F. et al . Irreversibility of kindled alcohol-withdrawal behaviour in rats.  Alcohol. 1998;  33 230-243
    Google Scholar
  • 20 De Witte P, Pinto E, Ansseau M. et al . Alcohol and withdrawal: from animal research to clinical issues.  Neurosci Biobehav Rev. 2003;  27 189-197
    Google Scholar
  • 21 Bachteler D, Spanagel R. Glutamatergic compounds: a perspective. Spanagel R, Mann K Drugs for Relapse Prevention of Alcoholism Basel; Birkhäuser-Verlag 2005: 205-216
    Google Scholar
  • 22 Gass J T, Olive M F. Glutamatergic substrates of drug addiction and alcoholism.  Biochem Pharmacol. 2008;  75 (1) 218-265
    Google Scholar
  • 23 Temkin N R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: a meta-analysis of controlled trials.  Epilepsia. 2001;  42 515-525
    Google Scholar
  • 24 White H S, Smith M D, Wilcox K S. Mechanisms of action of antiepileptic drugs.  Int Rev Neurobiol. 2007;  81 85-110
    Google Scholar
  • 25 Malcolm R, Myrick H, Brady K T. et al . Update on anticonvulsants for the treatment of alcohol withdrawal.  Am J Addict. 2001;  10 (Suppl) 16-23
    Google Scholar
  • 26 Book S W, Myrick H. Novel anticonvulsants in the treatment of alcoholism.  Expert Opin Investig Drugs. 2005;  14 371-376
    Google Scholar
  • 27 Roberto M, Gilpin N W, O’Dell L E. et al . Cellular and behavioural interactions of gabapentin with alcohol dependence.  J Neuroscience. 2008;  28 5762-5771
    Google Scholar
  • 28 Braus D F, Wrase J, Grüsser S. et al . Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics.  J Neural Transm. 2001;  108 887-894
    Google Scholar
  • 29 Myrick H, Anton R A, Li X. et al . Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving.  Neuropsychopharmacol. 2004;  29 393-402
    Google Scholar
  • 30 Bonnet U, Bingmann D, Leniger T. et al . Valproate acidifies hippocampal CA 3-neurones – a novel mode of action.  Eur Neuropsychopharmacol. 2002;  12 279-285
    Google Scholar
  • 31 Leniger T, Thöne J, Bonnet U. et al . Levetiracetam inhibits Na + -dependent Cl-/HCO3- -exchange of adult hippocampal CA 3 neurones from guinea-pigs.  Br J Pharmacol. 2004a;  142 1073-1080
    Google Scholar
  • 32 Leniger T, Thöne J, Wiemann M. Topiramate modulates pH of hippocampal CA 3 neurons by combined effects on carbonic anhydrase and Cl-/HCO3- -exchange.  Br J Pharmacol. 2004b;  142 831-842
    Google Scholar
  • 33 Davies A, Hendrich J, Van Minh A T. et al . Functional biology of the alpha (2) delta subunits of voltage-gated calcium channels.  Trends Pharmacol Sci. 2007;  28 220-228
    Google Scholar
  • 34 De Smedt T, Raedt R, Vonck K. et al . Levetiracetam: the profile of a novel anticonvulsant drug – part I: preclinical data.  CNS Drug Rev. 2007;  13 43-56
    Google Scholar
  • 35 Das Leitlinienmanual von AWMF und ÄZQ. Systematische Evidenz-Recherche.  ZaeFQ. 2001;  95 (Suppl 1)
    Google Scholar
  • 36 Mayo-Smith M F, Beecher L H, Fisher T L. et al . Management of alcohol withdrawal delirium. An evidence-based practice guideline.  Arch Intern Med. 2004;  164 1405-1412
    Google Scholar
  • 37 DeBellis R, Smith B S, Choi S. et al . Management of Delirium tremens.  J Intensiv Care Med. 2005;  20 164-173
    Google Scholar
  • 38 Hillbom M, Pieninkeroinen I, Leone M. Seizures in alcohol-dependent patients.  CNS drugs. 2003;  17 1013-1030
    Google Scholar
  • 39 Rathlev N K, Ulrich A S, Delanty N. et al . Alcohol-related seizures.  J Emerg Med. 2006;  31 157-163
    Google Scholar
  • 40 Allain H, Bentue-Ferrer D, Polard E. et al . Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.  Drugs Aging. 2005;  22 749-765
    Google Scholar
  • 41 Paterniti S, Dufouil C, Alperovitch A. Long term benzodiazepine use and cognitive decline in the eldery: the epidemiology of vascular aging study.  J Clin Psychopharmacol. 2002;  22 285-293
    Google Scholar
  • 42 Sellers E M, Naranjo C A, Harrison M. et al . Diazepam loading: simplified treatment of alcohol withdrawal.  Clin Pharmacol Ther. 1983;  34 822-826
    Google Scholar
  • 43 Naranjo C A, Sellers E M, Chater K. et al . Nonpharmacologic intervention in acute alcohol withdrawal.  Clin Pharmacol Ther. 1983;  34 (2) 214-219
    Google Scholar
  • 44 Burroughs A K, Morgan M Y, Sherlock S. Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms.  Alcohol. 1985;  20 263-271
    Google Scholar
  • 45 Mayo-Smith M F. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol withdrawal.  JAMA. 1997;  278 144-151
    Google Scholar
  • 46 Holbrook A M, Crowther R, Lotter A. et al . Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal.  CMAJ. 1999;  160 649-655
    Google Scholar
  • 47 Ntais C, Pakos E, Kyzas P. et al . Benzodiazepines for alcohol withdrawal.  Cochrane Database Syst Rev. 2005;  3 CD005063
    Google Scholar
  • 48 Glatt M M, George H R, Frisch E P. Evaluation of chlormethiazole in the treatment for alcohol withdrawal syndrome. Results of a controlled trial.  Acta Psychiatr Scand. 1966;  192 (Suppl) 121-137
    Google Scholar
  • 49 Majumdar S K. Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome.  Drug Alcohol Depend. 1991;  27 201-207
    Google Scholar
  • 50 Polycarpou A, Papanikolaou P, Ioannidis J PA. Anticonvulsants for alcohol withdrawal (review).  Cochrane Database Syst Rev. 2005;  3 CD005064
    Google Scholar
  • 51 Bjorkqvist S E, Isohanni M, Mäkelä R. et al . Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo.  Acta Psychiatr Scand. 1976;  53 333-342
    Google Scholar
  • 52 Hillbom M, Tokola R, Kuusela V. et al . Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid.  Alcohol. 1989;  6 223-226
    Google Scholar
  • 53 Ritola E, Malinen L. A double-blind comparison of carbamazepine and chlomethiazole in the treatment of alcohol withdrawal syndrome.  Acta Psychiatr Scand. 1981;  64 254-259
    Google Scholar
  • 54 Seifert J, Peters E, Jahn K. Treatment of alcohol withdrawal: chlormethiazole versus carbamazepine and the effect on memory performance – a pilot study.  Addict Biol. 2004;  9 43-51
    Google Scholar
  • 55 Stuppaeck C H, Pycha R, Müller C. et al . Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study.  Alcohol. 1992;  27 153-158
    Google Scholar
  • 56 Malcolm R, Myrick H, Roberts J. et al . The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial.  J Gen Int Med. 2002;  17 349-355
    Google Scholar
  • 57 Schik G, Wedegaertner F R, Liersch J. et al . Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal.  Addict Biol. 2005;  10 (3) 283-288
    Google Scholar
  • 58 Agricola R, Mazzarino M, Urani R. et al . Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride.  J Int Med Res. 1982;  10 150-155
    Google Scholar
  • 59 Soyka M, Morhart-Klute V, Horak M. A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study.  Eur Arch Psychiatry Clin Neurosci. 2002;  252 197-200
    Google Scholar
  • 60 Soyka M, Schmidt P, Franz M. et al . Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients.  Eur Arch Psychiatry Clin Neurosci. 2006;  256 395-401
    Google Scholar
  • 61 Reoux J P, Saxon A J, Malte C A. et al . Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.  Alcohol Clin Exp Res. 2001;  25 1324-1329
    Google Scholar
  • 62 Lambie D G, Johnson R H, Vijayasenan M E. et al . Sodium valproate in the treatment of alcohol withdrawal syndrome.  Aust NZ J Psychiatry. 1980;  14 213-215
    Google Scholar
  • 63 Rosenthal R N, Perkel C, Singh P. et al . A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal.  Am J Addict. 1998;  7 189-197
    Google Scholar
  • 64 Myrick H, Brady K T, Malcolm R. Divalproex in the treatment of alcohol withdrawal.  Am J Drug Alcohol Abuse. 2000;  26 155-160
    Google Scholar
  • 65 Longo L P, Campbell T, Hubatch S. Divalproex sodium (Dekapote) for alcohol withdrawal and relapse prevention.  J Addict Dis. 2002;  21 55-64
    Google Scholar
  • 66 Aliyev Z N, Aliyev N A. Valproat treatment of acute alcohol halluzinosis: a double-blind, placebo-controlled study.  Alcohol. 2008;  43 456-459
    Google Scholar
  • 67 Koethe D, Juelicher A, Nolden B M. et al . Oxcarbazepine – efficacy and tolerability during treatment of alcohol withdrawal : a double-blind, randomized, placebo-controlled multicenter pilot study.  Alcohol Clin Exp Res. 2007;  31 1188-1194
    Google Scholar
  • 68 Ponce G, Rodiguez-Jimenez R, Ortiz H. et al . Oxcarbazepine in the prevention of epileptic syndromes in alcohol detoxification.  Rev Neurol. 2005;  40 (10) 577-580
    Google Scholar
  • 69 Krupitsky E M, Rudenko A A, Burakov A M. et al . Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.  Alcohol Clin Exp Res. 2007;  31 604-611
    Google Scholar
  • 70 Rustembegovic A, Sofic E, Kroyer G. A pilot study of topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes.  Med Arh. 2002;  56 211-212
    Google Scholar
  • 71 Stuppaeck C H, Deisenhammer E A, Kurz M. et al . The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome.  Alcohol Alcohol. 1996;  31 109-111
    Google Scholar
  • 72 Myrick H, Taylor B, LaRowe S. et al . A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal.  J Psychoactive Drugs. 2005;  37 409-414
    Google Scholar
  • 73 Bonnet U, Banger M, Leweke F M. et al . Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.  J Clin Psychopharmacol. 2003;  23 514-519
    Google Scholar
  • 74 Bonnet U, Specka M, Leweke F M. et al . Gabapentin’s acute effect on mood profile – a controlled study on patients with alcohol withdrawal.  Prog Neuropsychopharmacol Biol Psychiatr. 2007;  31 434-438
    Google Scholar
  • 75 Mariani J J, Rosenthal R N, Tross S. et al . A randomized, open label trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal.  Am J Addict. 2006;  15 76-84
    Google Scholar
  • 76 Voris J, Smith N L, Rao S M. et al . Gabapentin for the treatment of ethanol withdrawal.  Subst Abus. 2003;  24 129-132
    Google Scholar
  • 77 Rustembegovic A, Sofic E, Tahiroviä I. et al . A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome.  Med Arh. 2004;  58 5-6
    Google Scholar
  • 78 Krebs M, Leopold K, Richter C. et al . Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.  J Clin Psychopharmacol. 2006;  26 347-349
    Google Scholar
  • 79 Benideto M A, Leite J R. Baclofen as an anticonvulsant in experimental models of convulsions.  Exp Neurol. 1981;  72 346-351
    Google Scholar
  • 80 Carai M A, Brunetti G, Lobina C. et al . Proconvulsive effect of the GABA (B) receptor antagonist, SCH 50 911, in rats undergoing ethanol withdrawal syndrome.  Eur J Pharmacol. 2002;  445 195-199
    Google Scholar
  • 81 Addolorato G, Leggio L, Abenavoli L. et al . Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs. diazepam.  Am J Med. 2006;  119 (3) 276.e13-18
    Google Scholar
  • 82 Kosten T R, O’Conner P G. Management of Drug and Alcohol Withdrawal.  N Engl J Med. 2003;  348 1786-1795
    Google Scholar
  • 83 Malcolm R, Myrick H, Veatch L M. et al . Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin.  J Clin Sleep Med. 2007;  3 24-32
    Google Scholar
  • 84 Karam-Hage M, Brower K J. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.  Psychiatry Clin Neurosci. 2003;  57 542-544
    Google Scholar
  • 85 Bonnet U, Specka M, Hamzavi-Abedi R. et al . Severe protracted alcohol withdrawal syndrome: prevalence and pharmacological treatment at an inpatient detoxification unit – a naturalistic study.  Pharmacopsychiatry. 2009;  (im Druck)
    Google Scholar
  • 86 Mueller T, Stout R L, Brown R A. et al . A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.  Alcohol Clin Exp Res. 1997;  21 86-92
    Google Scholar
  • 87 Brady K T, Myrick H, Henderson S. et al . The use of divalproex in alcohol relapse prevention: a pilot study.  Drug Alcohol Depend. 2002;  67 323-330
    Google Scholar
  • 88 Croissant B, Diehl A, Klein O. et al . A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.  Alcohol Clin Exp Res. 2006;  30 630-635
    Google Scholar
  • 89 Marinotti G, Di Nicola M, Romanelli R. et al . High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.  Hum Psychopharmacol. 2007;  22 149-156
    Google Scholar
  • 90 Johnson B A, Ait-Dout N, Bowden C L. et al . Oral topiramate for treatment of alcohol dependence: a randomized controlled trial.  Lancet. 2003;  361 1677-1685
    Google Scholar
  • 91 Johnson B A, Ait-Dout N, Akhtar F Z. et al . Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial.  Arch Gen Psychiatry. 2004;  61 905-912
    Google Scholar
  • 92 Johnson B A, Rosenthal N, Capece J A. et al . Topiramate for treating alcohol dependence. A randomized controlled trial.  JAMA. 2007;  298 1641-1651
    Google Scholar
  • 93 Johnson B A, Rosenthal N, Capece J A. et al . Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multiside randomized controlled trial.  Arch Intern Med. 2008;  168 1188-1199
    Google Scholar
  • 94 Baltieri D A, Daro F R, Ribeiro P L. et al . Comparing topiramate with naltrexone in the treatment of alcohol dependence.  Addiction. 2009;  (im Druck)
    Google Scholar
  • 95 Florez G, Garcia-Portilla P, Alvarez S. et al . Using topiramate or naltrexone for the treatment of alcohol-dependent patients.  Alcohol Clin Exp Res. 2008;  32 1251-1259
    Google Scholar
  • 96 De Sousa A A, De Sousa J A, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence.  J Subst Abuse Treat. 2008;  34 460-463
    Google Scholar
  • 97 Rubio G, Ponce G, Jimenez-Arriero M A. et al . Effects of topiramate in treatment of alcohol dependence.  Pharmacopsychiatry. 2004;  37 37-40
    Google Scholar
  • 98 Addolorato G, Caputo F, Capristo E. et al . Ability of baclofen in reducing alcohol craving and intake: preliminary clinical evidence.  Alcohol Clin Exp Res. 2000;  24 57-71
    Google Scholar
  • 99 Addolorato G, Caputo F, Capristo E. et al . Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.  Alcohol. 2002;  37 504-508
    Google Scholar
  • 100 Addolorato G, Leggio L, Ferrulli A. et al . Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study.  Lancet. 2007;  370 1915-1922
    Google Scholar
  • 101 Sarid-Segal O, Piechniczek-Buczek J, Knapp C. et al . The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.  Am J Drug Alcohol Abuse. 2008;  34 441-447
    Google Scholar
  • 102 Furieri F A, Nakamura-Palacios E M. Gabapentin reduces alcohol consumption and craving. A randomized, double-blind, placebo-controlled trial.  J Clin Psychiatry. 2007;  68 1691-1700
    Google Scholar
  • 103 Brower K J, Kim H M, Strobbe S. et al . A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.  Alcohol Clin Exp Res. 2008;  32 1429-1438
    Google Scholar
  • 104 Mason B J, Light J M, Williams L D. et al . Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.  Addict Biol. 2009;  (im Druck)
    Google Scholar
  • 105 Martinotti G, Di Nicola M, Tedeschi D. et al . Efficacy and safety of pregabalin in alcohol dependence.  Adv Ther. 2008;  25 1-10
    Google Scholar
  • 106 Hertzman M. Divalproex sodium to treat concomitant substance abuse and mood disorders.  J Subst Abuse Treat. 2000;  18 371-372
    Google Scholar
  • 107 Brady K T, Sonne S C, Anton R. et al . Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study.  J Clin Psychiatry. 1995;  56 118-121
    Google Scholar
  • 108 Salloum I M, Cornelius J R, Daley D C. et al . Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.  Arch Gen Psychiatry. 2005;  62 37-45
    Google Scholar
  • 109 Rubio G, Lopez-Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.  Bipol Disord. 2006;  8 289-293
    Google Scholar
  • 110 Krupitsky E M, Burakov A M, Ivanov V B. et al . Baclofen administration for the treatment of affective disorders in alcoholic patients.  Drug Alcohol Depend. 1993;  33 157-163
    Google Scholar
  • 111 Bisaga A, Evans S M. The acute effects of gabapentin in combination with alcohol in heavy drinkers.  Drug Alcohol Depend. 2006;  83 25-32
    Google Scholar
  • 112 Myrick H, Anton R, Voronin K. et al . A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm.  Alcohol Clin Exp Res. 2007;  31 221-227
    Google Scholar
  • 113 Lucht M, Kuehn K U, Armbruster J. et al . Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam.  Alcohol. 2003;  38 168-175
    Google Scholar
  • 114 Mann K. Pharmacotherapy of alcohol dependence. A review of the clinical data.  CNS drugs. 2004;  18 485-504
    Google Scholar
  • 115 Soyka M, Roesner S. New pharmacological approaches for the treatment of alcoholism.  Expert Opin Pharmacother. 2006;  7 2341-2353
    Google Scholar

Prof. Dr. med. Udo Bonnet

LVR-Klinikum Essen, Klinik für abhängiges Verhalten und Suchtmedizin, Klinik für Psychiatrie und Psychotherapie, Universität Duisburg-Essen

Virchowstr. 174

45147 Essen

Email: udo.bonnet@uni-due.de